PT  - JOURNAL ARTICLE
AU  - Donald Banerji
AU  - Angel FowlerTaylor
AU  - Pearl Kho
AU  - Hungta Chen
AU  - Vijay Alagappan
TI  - Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P755
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P755.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P755.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - IntroductionQVA149 is a once daily, dual bronchodilator with a fixed-dose combination of indacaterol (a long-acting β2-agonist) and glycopyrronium (a long-acting muscarinic antagonist) for treatment of patients with COPD. We present the pooled analysis of lung function data from severe patients from the QVA149 SPARK, ARISE, and ENLIGHTEN studies.MethodsData from 1871 patients with severe COPD (stage III; post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30-<50% of predicted and FEV1/FVC <70%) were pooled (QVA149 [110/50µg] = 696; glycopyrronium [50µg] = 584; tiotropium [18µg] = 591). FEV1 and forced vital capacity (FVC) were analyzed using ANCOVA.ResultsDemographics and baseline characteristics were balanced across the treatment groups; overall 63.8 yrs mean age, 80.1% Caucasians, 6.9 yrs mean duration of COPD, 72.4% patients used inhaled corticosteroids at baseline, 37.9% current smoker, and 41.4% of FEV1/FVC. Pre-dose FEV1 and FVC were significantly greater with QVA149 than glycopyrronium and tiotropium at all visits (p<0.001). Spirometric analyses of QVA149 vs. glycopyrronium and tiotropium after 52 weeks of treatment are shown in table.View this table:Table: Treatment differences in lung functionConclusionQVA149 improved lung function significantly better than glycopyrronium and tiotropium in patients with severe COPD at Week 52.